KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Long-Term Deferred Tax (2018 - 2020)

Ionis Pharmaceuticals (IONS) has disclosed Long-Term Deferred Tax for 5 consecutive years, with $307.7 million as the latest value for Q3 2020.

  • For Q3 2020, Long-Term Deferred Tax rose 7.98% year-over-year to $307.7 million; the TTM value through Sep 2020 reached $307.7 million, up 7.98%, while the annual FY2019 figure was $305.6 million, 5.08% up from the prior year.
  • Long-Term Deferred Tax hit $307.7 million in Q3 2020 for Ionis Pharmaceuticals, up from $306.0 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $309.6 million in Q1 2020 and bottomed at $276.4 million in Q2 2019.
  • Average Long-Term Deferred Tax over 3 years is $294.8 million, with a median of $298.2 million recorded in 2018.
  • Year-over-year, Long-Term Deferred Tax increased 5.08% in 2019 and then grew 11.67% in 2020.
  • Ionis Pharmaceuticals' Long-Term Deferred Tax stood at $290.8 million in 2018, then increased by 5.08% to $305.6 million in 2019, then grew by 0.71% to $307.7 million in 2020.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $307.7 million, $306.0 million, and $309.6 million for Q3 2020, Q2 2020, and Q1 2020 respectively.